Skip to main content
. Author manuscript; available in PMC: 2019 Apr 19.
Published in final edited form as: ACS Chem Biol. 2019 Mar 12;14(4):751–757. doi: 10.1021/acschembio.9b00032

Figure 3.

Figure 3.

Pharmacokinetic profile of fulvestrant after intravenous administration. Plasma concentration of fulvestrant (initial dose, ID = 6 mg/kg, formulated at 1250 μM) administered as (A) stable colloids (0.03% UP80) or (B) monomer (5% UP80). Trend line denotes exponential decay fitting of lambda elimination phase. (C) Pharmacokinetic parameters of fulvestrant show almost 4-fold increase in drug half-life with colloids compared to monomer (n = 3–6, mean + SD).